| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Activation | 57 | 2024 | 645 | 9.260 |
Why?
|
| Blood Platelets | 81 | 2024 | 2479 | 8.900 |
Why?
|
| Platelet Function Tests | 27 | 2024 | 271 | 3.420 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 771 | 3.380 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 284 | 3.230 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 2751 | 3.200 |
Why?
|
| Flow Cytometry | 32 | 2024 | 5869 | 2.520 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 577 | 2.470 |
Why?
|
| Blood Platelet Disorders | 7 | 2024 | 60 | 2.330 |
Why?
|
| Ticlopidine | 19 | 2018 | 730 | 2.290 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 115 | 2.190 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 72 | 2.090 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 7 | 2024 | 144 | 1.940 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 422 | 1.910 |
Why?
|
| P-Selectin | 20 | 2021 | 597 | 1.850 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 40 | 1.810 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 178 | 1.680 |
Why?
|
| Hemostasis | 7 | 2024 | 467 | 1.590 |
Why?
|
| Thiophenes | 12 | 2018 | 569 | 1.570 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 67 | 1.390 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 109 | 1.350 |
Why?
|
| Platelet Count | 8 | 2021 | 781 | 1.340 |
Why?
|
| Piperazines | 13 | 2013 | 2523 | 1.230 |
Why?
|
| CD40 Ligand | 8 | 2023 | 522 | 1.150 |
Why?
|
| Aspirin | 16 | 2018 | 3133 | 1.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 242 | 1.030 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 1063 | 0.940 |
Why?
|
| Serotonin | 3 | 2024 | 1041 | 0.890 |
Why?
|
| Thrombasthenia | 6 | 2022 | 21 | 0.880 |
Why?
|
| Sudden Infant Death | 2 | 2024 | 292 | 0.870 |
Why?
|
| 14-3-3 Proteins | 1 | 2024 | 220 | 0.850 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 32 | 0.830 |
Why?
|
| Integrin beta3 | 4 | 2018 | 120 | 0.770 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 445 | 0.740 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 440 | 0.740 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 702 | 0.710 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1154 | 0.700 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 143 | 0.700 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1869 | 0.680 |
Why?
|
| Electricity | 3 | 2021 | 181 | 0.680 |
Why?
|
| Platelet Membrane Glycoproteins | 16 | 2016 | 284 | 0.660 |
Why?
|
| Drug Resistance | 5 | 2009 | 1596 | 0.620 |
Why?
|
| Hematologic Agents | 1 | 2018 | 40 | 0.610 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 97 | 0.600 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1182 | 0.600 |
Why?
|
| Hemorrhage | 7 | 2021 | 3424 | 0.600 |
Why?
|
| Megakaryocytes | 2 | 2022 | 567 | 0.590 |
Why?
|
| Dog Diseases | 1 | 2018 | 141 | 0.590 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 165 | 0.550 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 154 | 0.550 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 1651 | 0.550 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 161 | 0.500 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 2190 | 0.460 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 574 | 0.420 |
Why?
|
| Adenosine | 2 | 2017 | 808 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 21 | 2013 | 9177 | 0.390 |
Why?
|
| Omeprazole | 1 | 2012 | 105 | 0.380 |
Why?
|
| Thiazoles | 1 | 2018 | 1517 | 0.370 |
Why?
|
| Humans | 127 | 2024 | 761572 | 0.360 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 532 | 0.350 |
Why?
|
| Leukocytes | 8 | 2016 | 2026 | 0.350 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 13 | 0.350 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 618 | 0.350 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 130 | 0.340 |
Why?
|
| Liver Diseases | 1 | 2018 | 1298 | 0.340 |
Why?
|
| Thrombin | 9 | 2021 | 591 | 0.340 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2023 | 131 | 0.330 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1462 | 0.330 |
Why?
|
| Pyrazoles | 5 | 2019 | 2009 | 0.310 |
Why?
|
| Clot Retraction | 1 | 2007 | 13 | 0.300 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 1134 | 0.300 |
Why?
|
| Communication | 2 | 2022 | 3873 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3701 | 0.290 |
Why?
|
| Cardiology | 1 | 2018 | 1656 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 10766 | 0.290 |
Why?
|
| Factor Va | 2 | 2021 | 10 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 7 | 2017 | 1601 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 3810 | 0.260 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 427 | 0.260 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 6403 | 0.260 |
Why?
|
| Prodrugs | 1 | 2007 | 261 | 0.260 |
Why?
|
| Fibrinogen | 7 | 2006 | 888 | 0.250 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 365 | 0.250 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 2079 | 0.240 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 244 | 0.230 |
Why?
|
| Dogs | 7 | 2018 | 3839 | 0.230 |
Why?
|
| Double-Blind Method | 12 | 2019 | 12341 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 597 | 0.220 |
Why?
|
| Peptides | 4 | 2013 | 4358 | 0.220 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4243 | 0.220 |
Why?
|
| Thrombelastography | 3 | 2018 | 187 | 0.220 |
Why?
|
| Male | 58 | 2024 | 360842 | 0.210 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 15501 | 0.210 |
Why?
|
| Female | 56 | 2024 | 392686 | 0.200 |
Why?
|
| Phosphoproteins | 5 | 2017 | 2448 | 0.200 |
Why?
|
| Benzoates | 2 | 2015 | 212 | 0.200 |
Why?
|
| Tyrosine | 3 | 2003 | 1440 | 0.200 |
Why?
|
| Hydrazines | 2 | 2015 | 224 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2015 | 103 | 0.200 |
Why?
|
| Gaucher Disease | 1 | 2021 | 110 | 0.180 |
Why?
|
| Eczema | 1 | 2023 | 246 | 0.180 |
Why?
|
| Calgranulin A | 1 | 2021 | 80 | 0.180 |
Why?
|
| Calgranulin B | 1 | 2021 | 86 | 0.180 |
Why?
|
| Kinetics | 7 | 2017 | 6374 | 0.180 |
Why?
|
| Monocytes | 6 | 2015 | 2570 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 462 | 0.170 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 389 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1736 | 0.170 |
Why?
|
| Middle Aged | 40 | 2021 | 220920 | 0.170 |
Why?
|
| Phenotype | 7 | 2023 | 16592 | 0.160 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 48 | 0.160 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2084 | 0.160 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 51 | 0.160 |
Why?
|
| Case-Control Studies | 10 | 2018 | 22176 | 0.160 |
Why?
|
| Cattle | 7 | 2019 | 3849 | 0.160 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 231 | 0.150 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 753 | 0.150 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 396 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2013 | 1638 | 0.150 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 94 | 0.150 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 188 | 0.150 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 214 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2013 | 1416 | 0.150 |
Why?
|
| Thrombosis | 6 | 2024 | 2942 | 0.150 |
Why?
|
| Hemophilia A | 1 | 2021 | 360 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 233 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6312 | 0.140 |
Why?
|
| Calpain | 1 | 2017 | 146 | 0.140 |
Why?
|
| Asphyxia | 1 | 2017 | 60 | 0.140 |
Why?
|
| Adult | 32 | 2021 | 221203 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 695 | 0.140 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 238 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 385 | 0.130 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 24 | 0.130 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 973 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 77 | 0.130 |
Why?
|
| Drug Stability | 1 | 2015 | 291 | 0.120 |
Why?
|
| Cell Adhesion | 5 | 2003 | 3088 | 0.120 |
Why?
|
| Antibodies | 2 | 2023 | 2418 | 0.120 |
Why?
|
| Gastroparesis | 1 | 2017 | 136 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2021 | 1526 | 0.120 |
Why?
|
| Factor V | 2 | 2008 | 167 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4853 | 0.120 |
Why?
|
| Integrins | 4 | 1993 | 834 | 0.120 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1725 | 0.110 |
Why?
|
| Collagen | 5 | 2009 | 2638 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 490 | 0.110 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 405 | 0.110 |
Why?
|
| Drug Monitoring | 3 | 2021 | 962 | 0.110 |
Why?
|
| Stereoisomerism | 1 | 2014 | 614 | 0.110 |
Why?
|
| Time Factors | 9 | 2018 | 39970 | 0.110 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 64 | 0.100 |
Why?
|
| Methionine | 2 | 1986 | 572 | 0.100 |
Why?
|
| Pain | 2 | 2021 | 5073 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1394 | 0.100 |
Why?
|
| Reference Values | 2 | 2012 | 4920 | 0.100 |
Why?
|
| Peptide Fragments | 7 | 2015 | 5112 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 12148 | 0.100 |
Why?
|
| International Cooperation | 1 | 2018 | 1422 | 0.100 |
Why?
|
| Cell Line | 3 | 2016 | 15601 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 64684 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 432 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1353 | 0.100 |
Why?
|
| Consensus | 1 | 2021 | 3123 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3076 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 983 | 0.100 |
Why?
|
| Young Adult | 13 | 2021 | 59255 | 0.100 |
Why?
|
| Infant | 4 | 2024 | 36192 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10448 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 386 | 0.090 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 88 | 0.090 |
Why?
|
| Vascular Patency | 3 | 2009 | 911 | 0.090 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 143 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 220 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 1779 | 0.090 |
Why?
|
| Neutrophils | 5 | 2022 | 3767 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1334 | 0.090 |
Why?
|
| Animals | 27 | 2022 | 168467 | 0.090 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 9 | 0.090 |
Why?
|
| Adolescent | 11 | 2021 | 88324 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 803 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 23 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2012 | 290 | 0.090 |
Why?
|
| Parathyroid Hormone | 3 | 1986 | 1803 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 145 | 0.080 |
Why?
|
| Aged | 18 | 2019 | 169310 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1188 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2021 | 284 | 0.080 |
Why?
|
| Thromboplastin | 2 | 2007 | 286 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4431 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 1720 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 298 | 0.080 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Biotransformation | 1 | 2007 | 166 | 0.070 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15266 | 0.070 |
Why?
|
| ROC Curve | 1 | 2015 | 3579 | 0.070 |
Why?
|
| Sepsis | 1 | 2022 | 2585 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 20099 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2019 | 3028 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3492 | 0.070 |
Why?
|
| Calcium | 4 | 2021 | 5722 | 0.070 |
Why?
|
| Chest Pain | 1 | 2014 | 1091 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2013 | 8321 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 613 | 0.070 |
Why?
|
| Epitopes | 5 | 1992 | 2503 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2024 | 26198 | 0.070 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 279 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 450 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 26127 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11530 | 0.070 |
Why?
|
| Glycoproteins | 4 | 2002 | 2203 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.070 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 1285 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 3397 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 69 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3615 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 581 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2927 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3905 | 0.070 |
Why?
|
| Oligopeptides | 5 | 1993 | 1187 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2010 | 617 | 0.070 |
Why?
|
| Antigens, Surface | 2 | 1986 | 1606 | 0.060 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 1410 | 0.060 |
Why?
|
| Dalteparin | 2 | 2003 | 44 | 0.060 |
Why?
|
| Blood Cells | 1 | 2007 | 305 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 42230 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5672 | 0.060 |
Why?
|
| Cell Communication | 3 | 2022 | 1657 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2805 | 0.060 |
Why?
|
| Protein Conformation | 5 | 2001 | 3968 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3415 | 0.060 |
Why?
|
| Heterozygote | 2 | 2011 | 2787 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2018 | 4812 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1370 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4471 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6567 | 0.060 |
Why?
|
| Binding, Competitive | 4 | 2001 | 1141 | 0.060 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 28 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 9319 | 0.050 |
Why?
|
| Tissue Fixation | 2 | 2001 | 241 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9646 | 0.050 |
Why?
|
| Laboratories | 1 | 2007 | 458 | 0.050 |
Why?
|
| Endothelium | 2 | 2003 | 765 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3677 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 481 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 429 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 161 | 0.050 |
Why?
|
| Amino Acid Sequence | 11 | 1992 | 13446 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2690 | 0.050 |
Why?
|
| Gene Expression | 1 | 2015 | 7581 | 0.050 |
Why?
|
| Genotype | 5 | 2017 | 12990 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 23447 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11461 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1896 | 0.050 |
Why?
|
| Protein Binding | 3 | 2002 | 9353 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2001 | 54 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3617 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1844 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 73 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 981 | 0.050 |
Why?
|
| Comorbidity | 1 | 2015 | 10508 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 730 | 0.040 |
Why?
|
| Coronary Disease | 3 | 2005 | 5914 | 0.040 |
Why?
|
| Hirudins | 1 | 2001 | 179 | 0.040 |
Why?
|
| Child | 4 | 2018 | 80156 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2021 | 397 | 0.040 |
Why?
|
| Hemostatics | 1 | 2003 | 241 | 0.040 |
Why?
|
| Rats | 3 | 2015 | 23741 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2576 | 0.040 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18253 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2022 | 364 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8540 | 0.040 |
Why?
|
| Inflammation | 5 | 2022 | 10773 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6484 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 348 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 2064 | 0.040 |
Why?
|
| Heparin | 3 | 2003 | 1634 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2003 | 888 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1213 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1541 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2330 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2007 | 4124 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 675 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1756 | 0.040 |
Why?
|
| Epinephrine | 3 | 2008 | 792 | 0.040 |
Why?
|
| Calcitonin | 4 | 1980 | 329 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1875 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 8466 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 93 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2472 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2017 | 56 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 74213 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 520 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1702 | 0.040 |
Why?
|
| Molecular Sequence Data | 9 | 1992 | 17635 | 0.030 |
Why?
|
| Ligands | 4 | 1991 | 3272 | 0.030 |
Why?
|
| Binding Sites | 6 | 1993 | 6056 | 0.030 |
Why?
|
| E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
| Smoking | 2 | 2013 | 9053 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2014 | 54426 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 817 | 0.030 |
Why?
|
| Biological Availability | 1 | 2017 | 390 | 0.030 |
Why?
|
| Paresis | 1 | 2017 | 176 | 0.030 |
Why?
|
| Edetic Acid | 2 | 2004 | 280 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4465 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1998 | 273 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 324 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 532 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1971 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 148 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2000 | 7858 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7879 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1667 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 160 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 50 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 18965 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 320 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 507 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1009 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1303 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14666 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1574 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8633 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12059 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1569 | 0.020 |
Why?
|
| Brain Stem | 1 | 2017 | 858 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1991 | 138 | 0.020 |
Why?
|
| Carbazoles | 1 | 2013 | 220 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2013 | 238 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2011 | 83 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2001 | 4001 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 371 | 0.020 |
Why?
|
| United States | 1 | 2018 | 72335 | 0.020 |
Why?
|
| Cell Membrane | 5 | 2005 | 3687 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 560 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 64 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 623 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1596 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6075 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 271 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1986 | 2231 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1739 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 12947 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15843 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 541 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1171 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 168 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 83 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1990 | 510 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 781 | 0.020 |
Why?
|
| Temperature | 2 | 2011 | 2226 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1060 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1986 | 563 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 857 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 723 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 679 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 95 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 771 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 350 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3085 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2016 | 2332 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1776 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1962 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 81533 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2273 | 0.020 |
Why?
|
| Methanol | 1 | 1986 | 92 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2005 | 239 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2850 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2005 | 5035 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1986 | 1510 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 86 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6597 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 6864 | 0.020 |
Why?
|
| Destrin | 1 | 2004 | 10 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 285 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3416 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 1984 | 73 | 0.010 |
Why?
|
| Cysteamine | 1 | 1984 | 24 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2004 | 91 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1986 | 982 | 0.010 |
Why?
|
| Factor Xa | 1 | 2005 | 167 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14607 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8181 | 0.010 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 42 | 0.010 |
Why?
|
| Amino Acids | 2 | 1992 | 1718 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2011 | 1347 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 110 | 0.010 |
Why?
|
| Polysomnography | 1 | 2011 | 1848 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2013 | 2556 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2011 | 834 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2571 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3548 | 0.010 |
Why?
|
| Ibuprofen | 1 | 2005 | 229 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2414 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 1067 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1371 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 387 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1091 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 391 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14416 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39107 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2395 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 42 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1981 | 169 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 7047 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 393 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 10212 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1860 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2177 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 2496 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 202 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1463 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 754 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 243 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 596 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 872 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4425 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 516 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 108 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9469 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 685 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23996 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2009 | 4160 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22172 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1984 | 3597 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3267 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2218 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1981 | 774 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 818 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4575 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 832 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 702 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9489 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1808 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1687 | 0.010 |
Why?
|
| Mutation | 2 | 1992 | 30054 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4481 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8481 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8528 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12725 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1979 | 2016 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2006 | 3096 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 2048 | 0.010 |
Why?
|
| Base Sequence | 3 | 1992 | 12441 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 5890 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1980 | 861 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41493 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7237 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 12954 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17904 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4352 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13510 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29629 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 6534 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18398 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 664 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 416 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12794 | 0.010 |
Why?
|
| Vitronectin | 1 | 1989 | 40 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11076 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1989 | 47 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1058 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 1387 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 1741 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 209 | 0.000 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 1693 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2468 | 0.000 |
Why?
|
| Cricetinae | 1 | 1992 | 2423 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1989 | 813 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1990 | 576 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1434 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3049 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 2186 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 58986 | 0.000 |
Why?
|
| DNA | 2 | 1992 | 7213 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1979 | 2332 | 0.000 |
Why?
|
| Sialoglycoproteins | 1 | 1986 | 315 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 2645 | 0.000 |
Why?
|
| Lung Neoplasms | 2 | 1980 | 13382 | 0.000 |
Why?
|
| Pancreas | 1 | 1991 | 1691 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 4111 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2726 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1980 | 366 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1987 | 3733 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1979 | 645 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1979 | 2088 | 0.000 |
Why?
|
| Carcinoma | 2 | 1980 | 2330 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1981 | 1791 | 0.000 |
Why?
|
| Parathyroid Glands | 1 | 1978 | 518 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1979 | 420 | 0.000 |
Why?
|
| Biological Assay | 1 | 1978 | 626 | 0.000 |
Why?
|
| Retina | 1 | 1986 | 2659 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1979 | 1229 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1980 | 4026 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1978 | 908 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1979 | 1440 | 0.000 |
Why?
|
| Adenocarcinoma | 2 | 1980 | 6346 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1979 | 4807 | 0.000 |
Why?
|
| Sex Factors | 1 | 1978 | 10553 | 0.000 |
Why?
|
| Aging | 1 | 1978 | 8711 | 0.000 |
Why?
|